Yissum - Research Development Company of the Hebrew University

New Target for the Treatment of Parkinson’s Disease

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

The proposed invention is a novel target, Phophoinositides, for the treatment of Parkinson’s disease, based on a new mechanism, associating increased levels of membrane phospholipids with alpha-Syn-related toxicity.
Key words: Parkinson’s disease; alpha-Synuclein; Phosphatidylinositol; phosphatidylinositol 4,5-bisphosphate (PI4,5P2); striosomes; axonal injury; axonal branching
Project ID : 6-2018-4627

Description of the technology

Keywords

Parkinson’s disease, PD, Central Nervous System, CNS

Current development stage

TRL3 - Hypothesis testing and intial POC demonstrated in limited number of in-vitro models;

Our Innovation

  • Parkinson disease (PD) is a long-term, progressive neurodegenerative disorder of thecentral nervous system, which results in motor and non-motor dysfunction. The disease is primarily related to loss of dopaminergic function. The market of Parkinson’s diseasetreatments is driven by the growth in aging population and the associated increase in the prevalence of PD, however , there is currently nocure for Parkinson's disease, with treatment mostly associated with Dopamine replacement therapy, directed at improving symptoms.
  • The Researcher identified a possibly new target , with proposed mechanism of action associated with α-Syn toxicity in PD. Initial pre-clinical results suggest a novel therapeutic approach , using specific inhibitors to stop progression of Parkinson’s disease.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Ronit Sharon
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • cns
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.